HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Details Strong Sovaldi Launch, Plans HCV Combo Pill Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Less than one month after U.S. approval, the HCV drug has posted sales of $139 million, with about 70% of use occurring in patients carrying genotype 1 of the virus. Gilead reported 21% sales growth for the fourth quarter of 2013, 15% for the full year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel